PDS Planning Inc Boosts Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

PDS Planning Inc boosted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 389.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,254 shares of the company’s stock after purchasing an additional 25,662 shares during the quarter. PDS Planning Inc’s holdings in Dr. Reddy’s Laboratories were worth $509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. lifted its stake in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Dr. Reddy’s Laboratories by 402.5% during the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock valued at $38,981,000 after buying an additional 1,977,419 shares in the last quarter. State Street Corp raised its position in shares of Dr. Reddy’s Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after buying an additional 16,641 shares in the last quarter. Mondrian Investment Partners LTD raised its position in shares of Dr. Reddy’s Laboratories by 356.7% during the 4th quarter. Mondrian Investment Partners LTD now owns 648,813 shares of the company’s stock valued at $10,245,000 after buying an additional 506,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after buying an additional 427,573 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.36 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.50 and a 52 week high of $16.89. The firm’s fifty day moving average is $13.78 and its 200 day moving average is $14.74. The firm has a market cap of $11.15 billion, a P/E ratio of 21.27 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.